Related Experiment Video
Updated: Jun 28, 2026

LED-Based In Vitro Screening for Assessing Photoactivable Molecules in Bacterial Photodynamic Inactivation
Published on: January 24, 2025
Spotlight on retapamulin in impetigo and other uncomplicated superficial skin infections
1Wolters Kluwer Health, Auckland, New Zealand. demail@adis.co.nz
Abstract:
Topical retapamulin (Altabax, Altargo) is the first pleuromutilin antibacterial approved for the treatment of uncomplicated superficial skin infections caused by Staphylococcus aureus (excluding methicillin-resistant S. aureus [MRSA]) and Streptococcus pyogenes in patients aged > or = 9 months. In the EU, retapamulin is indicated for use in patients with impetigo or with infected small lacerations, abrasions, or sutured wounds (without abscesses); in the US, it is indicated for use in patients with impetigo. Retapamulin has a novel site of action on bacterial ribosomes. In clinical trials in patients with impetigo, topical retapamulin 1% ointment twice daily for 5 days (the approved regimen) was superior to placebo; treatment with retapamulin was noninferior to that with topical fusidic acid. In patients with secondarily infected traumatic lesions, treatment with retapamulin was noninferior to that with oral cephalexin, although the efficacy of retapamulin was reduced in patients with MRSA infections or superficial abscesses. Retapamulin was well tolerated in both pediatric and adult patients, and the majority of adverse events were of mild to moderate severity. Thus, the introduction of topical retapamulin 1% ointment extends the treatment options available in the management of impetigo and uncomplicated secondarily infected traumatic lesions.
Insights
Topical retapamulin is a new antibiotic for uncomplicated skin infections like impetigo. It effectively treats Staphylococcus aureus and Streptococcus pyogenes, offering a safe and well-tolerated treatment option.
Area of Science:
- Dermatology
- Infectious Diseases
- Pharmacology
Background:
- Topical antibiotics are crucial for treating superficial skin infections.
- Pleuromutilin antibacterials represent a novel class with a unique mechanism of action.
- Staphylococcus aureus and Streptococcus pyogenes are common pathogens in skin infections.
Purpose of the Study:
- To evaluate the efficacy and safety of topical retapamulin for uncomplicated superficial skin infections.
- To compare retapamulin with placebo, fusidic acid, and cephalexin in clinical trials.
- To assess retapamulin's utility in treating impetigo and secondarily infected traumatic lesions.
Main Methods:
- Phase 3 clinical trials involving patients aged 9 months and older with impetigo or infected traumatic lesions.
- Application of topical retapamulin 1% ointment twice daily for 5 days.
- Comparison of retapamulin's efficacy against placebo, fusidic acid, and oral cephalexin.
Main Results:
- Topical retapamulin demonstrated superiority to placebo in impetigo treatment.
- Retapamulin was noninferior to topical fusidic acid and oral cephalexin for specific indications.
- Efficacy was reduced in methicillin-resistant Staphylococcus aureus (MRSA) infections and abscesses.
- The drug was well-tolerated with mild to moderate adverse events.
Conclusions:
- Topical retapamulin is an effective and safe treatment for uncomplicated superficial skin infections caused by susceptible bacteria.
- It provides a valuable new therapeutic option for impetigo and certain traumatic skin lesions.
- Its novel mechanism of action on bacterial ribosomes contributes to its utility.
Related Concept Videos
Acne Infection
Staphylococcal Skin Infections
Hand hygiene
Hand washing...
Clinical Significance of Antibiotic Resistance
Rocky Mountain Spotted Fever
Rapid Identification of Pathogens